Novo Nordisk looks to bolt-on acquisitions as pipeline setbacks mount
read at Endpoints ↗DealNeutral
Novo Nordisk CEO Maziar Mike Doustdar said on a media call that the pharma industry is tough for those who dislike setbacks and failure.
He highlighted recent disappointments in the company's pipeline, noting that several late-stage programs have not met expectations.
In response, the company is exploring bolt-on acquisitions to strengthen its portfolio and offset the pipeline challenges.
Analysts say the strategy could help sustain growth but also brings integration risk.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Novo Nordisk eyes bolt-on deals as pipeline disappointments pile up”
read at Endpoints ↗94 words · retrieved Aug 5
comments(0)
5-min edit window · permanent after that